WATERTOWN, Mass. -- (BUSINESS WIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) Gram-negative pathogens), today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11th at 3:00 p.m. Eastern Time. The conference will take place February 10 – 11 at the Waldorf Astoria in New York City.
A live audio webcast of the presentation will be available on the Company's website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 90 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, including many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy. Tetraphase has created more than 3,000 novel tetracycline analogs using its technology platform; in addition to eravacycline, Tetraphase has generated multiple preclinical antibiotic candidates that are currently being evaluated for clinical suitability.